Australia-based fertility specialist Virtus Health has a new showpiece clinic in Copenhagen. HBI hears it is targeting both locals and medical tourists, and speaks to a source to find out more about the appeal of the Danish market.
London headquartered global PE firm Cinven has submitted a non-binding offer to fully take over Europe's largest lab group Synlab, the company confirmed today, following speculation it was looking to take the group private.
For-profit demand in the UK is likely to remain high, as the UK government stalls on its plans to increase public sector capacity. HBI speaks to a UK-based consultant to find out more.
Czechia-based fertility group FutureLife continues to expand in Spain with its latest acquisition. HBI chats with a European fertility operator to find out what is making the Spanish market appealing to investors.
The Irish government is set to fund fertility treatment for eligible patients for the first time. HBI speaks to an Ireland-based operator to find out more.
Medigold, one of the UK’s largest occupational health care providers, is acquiring Health Management, a major competitor, in a deal that will make it the UK's largest provider of occupational health in terms of number of employees covered.
German health minister Karl Lauterbach’s attempt to stop “locust investors” from owning outpatient facilities could actually end up benefitting large PE firms. HBI speaks to sources in Germany to find out more.
Relationships between payors and providers can be notoriously tricky. As attendees at the recent IFC conference in Cape Town, South Africa heard, the difference is often over how value is defined - and as providers grow, the balance of power is shifting.
KPJ Healthcare Bhd, Malaysia’s second largest for-profit hospital group by revenue, is to sell its Indonesian hospital operations to rival Columbia Asia Healthcare. This will mark its exit from the country. Luxembourg-based PE firm CVC Capital Partners is reportedly considering buying a minority stake in the group.
Shareholders did not give UK hospital group Spire’s full year results a warm reception, despite a return to profit, generally strong financials, and the continued viability of the UK market. HBI talks to market experts to find out why.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.